Integral Health Asset Management LLC Cuts Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

Integral Health Asset Management LLC cut its holdings in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 29.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 900,000 shares of the biotechnology company's stock after selling 375,000 shares during the period. Integral Health Asset Management LLC owned about 1.82% of REGENXBIO worth $6,957,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. Hudson Bay Capital Management LP increased its holdings in shares of REGENXBIO by 43.3% in the 4th quarter. Hudson Bay Capital Management LP now owns 308,100 shares of the biotechnology company's stock worth $2,382,000 after buying an additional 93,100 shares during the last quarter. Graham Capital Management L.P. increased its holdings in shares of REGENXBIO by 59.8% in the 4th quarter. Graham Capital Management L.P. now owns 28,542 shares of the biotechnology company's stock worth $221,000 after buying an additional 10,677 shares during the last quarter. D. E. Shaw & Co. Inc. increased its holdings in shares of REGENXBIO by 15.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 63,377 shares of the biotechnology company's stock worth $490,000 after buying an additional 8,271 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of REGENXBIO by 8.5% in the 4th quarter. Deutsche Bank AG now owns 200,375 shares of the biotechnology company's stock worth $1,549,000 after buying an additional 15,722 shares during the last quarter. Finally, Corton Capital Inc. bought a new stake in shares of REGENXBIO in the 4th quarter worth about $103,000. 88.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

RGNX has been the topic of a number of research reports. Leerink Partners set a $24.00 target price on shares of REGENXBIO in a report on Tuesday, March 18th. Chardan Capital restated a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a report on Thursday, March 20th. The Goldman Sachs Group cut their price target on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. Royal Bank of Canada reiterated an "outperform" rating and set a $30.00 price target on shares of REGENXBIO in a report on Tuesday, January 21st. Finally, Morgan Stanley upped their price target on shares of REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $31.63.

REGENXBIO Price Performance

Shares of NASDAQ:RGNX traded up $0.25 during trading on Friday, reaching $8.89. 825,125 shares of the company were exchanged, compared to its average volume of 869,224. The firm has a market capitalization of $445.92 million, a PE ratio of -1.77 and a beta of 1.11. The business's fifty day simple moving average is $7.54 and its 200-day simple moving average is $7.98. REGENXBIO Inc. has a 12-month low of $5.04 and a 12-month high of $16.25.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.41 by ($0.29). The company had revenue of $89.01 million for the quarter, compared to analysts' expectations of $105.35 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. On average, sell-side analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Insider Transactions at REGENXBIO

In related news, Director Kenneth T. Mills sold 20,602 shares of REGENXBIO stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $7.91, for a total transaction of $162,961.82. Following the transaction, the director now directly owns 475,103 shares of the company's stock, valued at $3,758,064.73. This trade represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 12.79% of the company's stock.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.